AI is reshaping drug discovery and development by accelerating research timelines, optimizing clinical strategies, and improving manufacturing efficiency, but adoption brings a complex web of legal considerations that life sciences companies must navigate. This article, published in Drug Discovery World, examines regulatory pathways for AI-assisted drug development, intellectual property ownership challenges, data protection and privacy obligations arising from AI model training and outlines practical steps organizations can take to capture the benefits of AI while managing regulatory, IP, and contractual risks.
